Fanconi anaemia and cancer: An intricate relationship

Nature Reviews Cancer

Volumn 18, Issue 3, 2018, Pages 168-185

  Nalepa, Grzegorz ^a,b   Clapp, D Wade ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA PROTEIN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; FANCD2 PROTEIN, HUMAN; FANCONI ANEMIA GROUP D2 PROTEIN;

CANCER THERAPY; CELL CYCLE; CELL DIVISION; CENTROSOME; CYTOKINESIS; ENDOMITOSIS; FANCONI ANEMIA; GENOME; HETEROZYGOTE; HUMAN; INTERPHASE; M PHASE CELL CYCLE CHECKPOINT; MALIGNANT NEOPLASM; MEIOSIS; MITOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; ACUTE MYELOID LEUKEMIA; DNA REPAIR; GENETIC PREDISPOSITION; GENETICS; GENOMIC INSTABILITY; MUTATION; NEOPLASM; SQUAMOUS CELL CARCINOMA;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA, SQUAMOUS CELL; DNA REPAIR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASMS;

EID: 85042377713     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2017.116     Document Type: Review

References (254)

1. Lobitz, S. & Velleuer, E. Guido Fanconi (1892-1979): A jack of all trades. Nat. Rev. Cancer 6, 893-898 (2006).
2. Ameziane, N. et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat. Commun. 6, 8829 (2015).
3. Wang, A. T. et al. A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination. Mol. Cell 59, 478-490 (2015).
4. Tischkowitz, M. D. et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18, 420-425 (2004).
5. Tischkowitz, M. et al. Bi-Allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br. J. Haematol. 123, 469-471 (2003).
6. Hess, C. J. et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol. 30, 299-306 (2008).
7. Alter, B. P. & Rosenberg, P. S. VACTERL-H association and Fanconi anemia. Mol. Syndromol 4, 87-93 (2013).
8. Neveling, K., Endt, D., Hoehn, H. & Schindler, D. Genotype-phenotype correlations in Fanconi anemia. Mutat. Res. 668, 73-91 (2009).
9. Auerbach, A. D. Fanconi anemia and its diagnosis. Mutat. Res. 668, 4-10 (2009).
10. Shimamura, A. & Alter, B. P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 24, 101-122 (2010).
11. Zhu, A. X., D?Andrea, A. D., Sahani, D. V. & Hasserjian, R. P. Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver. N. Engl. J. Med. 354, 1828-1837 (2006).
12. Huck, K. et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age-A paradigm. Br. J. Haematol. 133, 188-197 (2006).
13. Rochowski, A. et al. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leuk. Res. 36, 29-31 (2012).
14. Sharma, R. & Nalepa, G. Evaluation and management of chronic pancytopenia. Pediatr. Rev. 37, 101-111 (2016).
15. Tamary, H. et al. Frequency and natural history of inherited bone marrow failure syndromes: The Israeli Inherited Bone Marrow Failure Registry. Haematologica 95, 1300-1307 (2010).
16. Rosenberg, P. S., Tamary, H. & Alter, B. P. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi anemia in the United States and Israel. Am. J. Med. Genet. A 155A, 1877-1883 (2011).
17. Callen, E. et al. A common founder mutation in FANCA underlies the world?s highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood 105, 1946-1949 (2005).
18. Rosendorff, J., Bernstein, R., Macdougall, L. & Jenkins, T. Fanconi anemia: Another disease of unusually high prevalence in the Afrikaans population of South Africa. Am. J. Med. Genet. 27, 793-797 (1987).
19. Yagasaki, H. et al. Two common founder mutations of the fanconi anemia group G gene FANCG/XRCC9 in the Japanese population. Hum. Mutat. 21, 555 (2003).
20. Morgan, N. V. et al. A common Fanconi anemia mutation in black populations of sub-Saharan Africa. Blood 105, 3542-3544 (2005).
21. Tipping, A. J. et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc. Natl Acad. Sci. USA 98, 5734-5739 (2001).
22. Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649-4654 (2002).
23. Hays, L. et al.Fanconi Anemia: Guidelines for Diagnosis and Management 4 edn (Fanconi Anemia Research Fund, 2014).
24. Kutler, D. I. et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249-1256 (2003).
25. Paustian, L. et al. Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. Pediatr. Hematol. Oncol. 33, 5-12 (2016).
26. Velazquez, I. & Alter, B. P. Androgens and liver tumors: Fanconi?s anemia and non-Fanconi?s conditions. Am. J. Hematol. 77, 257-267 (2004).
27. Schifferli, A. & Kuhne, T. Fanconi anemia: overview of the disease and the role of hematopoietic transplantation. J. Pediatr. Hematol. Oncol. 37, 335-343 (2015).
28. Torjemane, L. et al. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Pediatr. Blood Cancer 46, 496-500 (2006).
29. Alter, B. P. Fanconi anemia and the development of leukemia. Best Pract. Res. Clin. Haematol. 27, 214-221 (2014).
30. Alter, B. P. et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol. 150, 179-188 (2010).
31. Kutler, D. I. et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129, 106-112 (2003).
32. Rosenberg, P. S., Socie, G., Alter, B. P. & Gluckman, E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 105, 67-73 (2005).
33. Ellis, N. A. et al. The Bloom?s syndrome gene product is homologous to RecQ helicases. Cell 83, 655-666 (1995).
34. Ellis, N. A., Proytcheva, M., Sanz, M. M., Ye, T. Z. & German, J. Transfection of BLM into cultured bloom syndrome cells reduces the sister-chromatid exchange rate toward normal. Am. J. Hum. Genet. 65, 1368-1374 (1999).
35. Cunniff, C., Bassetti, J. A. & Ellis, N. A. Bloom?s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol. Syndromol 8, 4-23 (2017).
36. Wechsler, T., Newman, S. & West, S. C. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 471, 642-646 (2011).
37. Naim, V. & Rosselli, F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nature Cell Biol. 11, 761-768 (2009).
38. Schurman, S. H. et al. Direct and indirect roles of RECQL4 in modulating base excision repair capacity. Hum. Mol. Genet. 18, 3470-3483 (2009).
39. Croteau, D. L., Singh, D. K., Hoh Ferrarelli, L., Lu, H. & Bohr, V. A. RECQL4 in genomic instability and aging. Trends Genet. 28, 624-631 (2012).
40. Kitao, S. et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat. Genet. 22, 82-84 (1999).
41. Van Maldergem, L. et al. Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene. J. Med. Genet. 43, 148-152 (2006).
42. Siitonen, H. A. et al. The mutation spectrum in RECQL4 diseases. Eur. J. Hum. Genet. 17, 151-158 (2009).
43. Wang, L. L. et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J. Natl Cancer Inst. 95, 669-674 (2003).
44. Carlson, A. M., Lindor, N. M. & Litzow, M. R. Therapy-related myelodysplasia in a patient with Rothmund-Thomson syndrome. Eur. J. Haematol. 86, 536-540 (2011).
45. Kraemer, K. H. & DiGiovanna, J. J. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health. Photochem. Photobiol. 91, 452-459 (2015).
46. Bradford, P. T. et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J. Med. Genet. 48, 168-176 (2011).
47. Bogliolo, M. et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am. J. Hum. Genet. 92, 800-806 (2013).
48. Kashiyama, K. et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am. J. Hum. Genet. 92, 807-819 (2013).
49. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
50. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
51. Chen, S. & Parmigiani, G. Meta-Analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25, 1329-1333 (2007).
52. Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
53. Alter, B. P., Rosenberg, P. S. & Brody, L. C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J. Med. Genet. 44, 1-9 (2007).
54. Myers, K. et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr. Blood Cancer 58, 462-465 (2012).
55. Sawyer, S. L. et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 5, 135-142 (2015).
56. Domchek, S. M. et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 3, 399-405 (2013).
57. Xia, B. et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729 (2006).
58. Levitus, M. et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 37, 934-935 (2005).
59. Levran, O. et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet. 37, 931-933 (2005).
60. Easton, D. F. et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J. Med. Genet. 53, 298-309 (2016).
61. Berwick, M. et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 67, 9591-9596 (2007).
62. Laitman, Y. et al. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. Cancer Genet. 209, 70-74 (2016).
63. Thompson, E. R. et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 8, e1002894 (2012).
64. Couch, F. J. et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 65, 383-386 (2005).
65. Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336-2346 (2015).
66. Virts, E. L. et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum. Mol. Genet. 24, 5093-5108 (2015).
67. Kiiski, J. I. et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 111, 15172-15177 (2014).
68. Katzke, V. A., Kaaks, R. & Kuhn, T. Lifestyle and cancer risk. Cancer J. 21, 104-110 (2015).
69. Umar, A., Dunn, B. K. & Greenwald, P. Future directions in cancer prevention. Nat. Rev. Cancer 12, 835-848 (2012).
70. Feinberg, A. P., Koldobskiy, M. A. & Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284-299 (2016).
71. Shen, Y. et al. Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. Oncotarget 6, 20396-20403 (2015).
72. Xie, Y. et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br. J. Haematol. 111, 1057-1064 (2000).
73. van der Heijden, M. S., Yeo, C. J., Hruban, R. H. & Kern, S. E. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 63, 2585-2588 (2003).
74. Wreesmann, V. B., Estilo, C., Eisele, D. W., Singh, B. & Wang, S. J. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec. 69, 218-225 (2007).
75. Kais, Z. et al. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep. 15, 2488-2499 (2016).
76. Michl, J., Zimmer, J., Buffa, F. M., McDermott, U. & Tarsounas, M. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat. Struct. Mol. Biol. 23, 755-757 (2016).
77. Kauffmann, A. et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27, 565-573 (2008).
78. Ozawa, H. et al. FANCD2 mRNA overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer. Ann. Surg. Oncol. 17, 2341-2348 (2010).
79. Strub, T. et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 30, 2319-2332 (2011).
80. Bourseguin, J. et al. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Sci. Rep. 6, 36539 (2016).
81. Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189-203 (2012).
82. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
83. Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016-1036 (2017).
84. Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275-287 (2016).
85. Castro-Giner, F., Ratcliffe, P. & Tomlinson, I. The mini-driver model of polygenic cancer evolution. Nat. Rev. Cancer 15, 680-685 (2015).
86. Krem, M. M., Press, O. W., Horwitz, M. S. & Tidwell, T. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. Br. J. Haematol. 171, 13-28 (2015).
87. Barber, L. J., Davies, M. N. & Gerlinger, M. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr. Opin. Genet. Dev. 30, 1-6 (2015).
88. Shlush, L. I. & Hershkovitz, D. Clonal evolution models of tumor heterogeneity. Am. Soc. Clin. Oncol. Educ. Book, e662-5 (2015).
89. Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93-115 (2017).
90. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
91. Salazar-Roa, M. & Malumbres, M. Fueling the cell division cycle. Trends Cell Biol. 27, 69-81 (2017).
92. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81 (2015).
93. Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43-47 (2016).
94. Park, E. et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol. Cell 50, 908-918 (2013).
95. Awasthi, P., Foiani, M. & Kumar, A. ATM and ATR signaling at a glance. J. Cell Sci. 128, 4255-4262 (2015).
96. Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol. Cell 66, 801-817 (2017).
97. Warfel, N. A. & El-Deiry, W. S. p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 25, 52-58 (2013).
98. Collins, N. B. et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 113, 2181-2190 (2009).
99. Wang, X. et al. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol. Cell. Biol. 27, 3098-3108 (2007).
100. Singh, T. R. et al. ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions. Cancer Res. 73, 4300-4310 (2013).
101. Xie, J. et al. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J. Clin. Invest. 125, 1523-1532 (2015).
102. Yamamoto, K. N. et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc. Natl Acad. Sci. USA 108, 6492-6496 (2011).
103. Lachaud, C. et al. Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia. J. Cell Sci. 127, 2811-2817 (2014).
104. Gwon, G. H. et al. Crystal structure of a Fanconi anemia-Associated nuclease homolog bound to 5′ flap DNA: basis of interstrand cross-link repair by FAN1. Genes Dev. 28, 2276-2290 (2014).
105. Sobeck, A. et al. Fanconi anemia proteins are required to prevent accumulation of replication-Associated DNA double-strand breaks. Mol. Cell. Biol. 26, 425-437 (2006).
106. Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966-977 (2011).
107. Segurado, M. & Diffley, J. F. Separate roles for the DNA damage checkpoint protein kinases in stabilizing DNA replication forks. Genes Dev. 22, 1816-1827 (2008).
108. Pichierri, P. & Rosselli, F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 23, 1178-1187 (2004).
109. Schwab, R. A. et al. The Fanconi anemia pathway maintains genome stability by coordinating replication and transcription. Mol. Cell 60, 351-361 (2015).
110. Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106-116 (2012).
111. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467-480 (2011).
112. Kim, Y. et al. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 43, 142-146 (2011).
113. Stoepker, C. et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 43, 138-141 (2011).
114. Wang, R. et al. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1. Science 346, 1127-1130 (2014).
115. Smogorzewska, A. et al. A genetic screen identifies FAN1, a Fanconi anemia-Associated nuclease necessary for DNA interstrand crosslink repair. Mol. Cell 39, 36-47 (2010).
116. Long, D. T., Raschle, M., Joukov, V. & Walter, J. C. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science 333, 84-87 (2011).
117. Vaz, F. et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat. Genet. 42, 406-409 (2010).
118. Schwab, R. A., Blackford, A. N. & Niedzwiedz, W. ATR activation and replication fork restart are defective in FANCM-deficient cells. EMBO J. 29, 806-818 (2010).
119. Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell 39, 25-35 (2010).
120. Pace, P. et al. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 329, 219-223 (2010).
121. Renaud, E., Barascu, A. & Rosselli, F. Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells. Nucleic Acids Res. 44, 648-656 (2016).
122. Blunt, T. et al. Identification of a nonsense mutation in the carboxyl-Terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc. Natl Acad. Sci. USA 93, 10285-10290 (1996).
123. Houghtaling, S. et al. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum. Mol. Genet. 14, 3027-3033 (2005).
124. Bunting, S. F. et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol. Cell 46, 125-135 (2012).
125. Ceccaldi, R., Sarangi, P. & D?Andrea, A. D. The Fanconi anaemia pathway: new players and new functions. Nat. Rev. Mol. Cell Biol. 17, 337-349 (2016).
126. Lossaint, G. et al. FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. Mol. Cell 51, 678-690 (2013).
127. Nalepa, G. et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J. Clin. Invest. 123, 3839-3847 (2013)
128. Nam, H. J., Naylor, R. M. & van Deursen, J. M. Centrosome dynamics as a source of chromosomal instability. Trends Cell Biol. 25, 65-73 (2015).
129. Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282 (2009).
130. de Carcer, G. & Malumbres, M. A centrosomal route for cancer genome instability. Nature Cell Biol. 16, 504-506 (2014).
131. Abdul-Sater, Z. et al. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. Exp. Hematol. 43, 1031-1046.e12 (2015).
132. Vinciguerra, P., Godinho, S. A., Parmar, K., Pellman, D. & D?Andrea, A. D. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J. Clin. Invest. 120, 3834-3842 (2010).
133. Zou, J. et al. FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Biol. Open 2, 1022-1031 (2013).
134. Kim, S. et al. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity. Int. J. Biochem. Cell Biol. 45, 1953-1961 (2013).
135. Wang, H. F., Takenaka, K., Nakanishi, A. & Miki, Y. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. Cancer Res. 71, 68-77 (2011).
136. Magron, A., Elowe, S. & Carreau, M. The Fanconi anemia C protein binds to and regulates Stathmin-1 phosphorylation. PLoS ONE 10, e0140612 (2015).
137. Kupfer, G. M. et al. The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. Blood 90, 1047-1054 (1997).
138. Beretta, L., Dobransky, T. & Sobel, A. Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J. Biol. Chem. 268, 20076-20084 (1993).
139. Godek, K. M., Kabeche, L. & Compton, D. A. Regulation of kinetochore-microtubule attachments through homeostatic control during mitosis. Nat. Rev. Mol. Cell Biol. 16, 57-64 (2015).
140. London, N. & Biggins, S. Signalling dynamics in the spindle checkpoint response. Nat. Rev. Mol. Cell Biol. 15, 736-747 (2014).
141. Choi, E. et al. BRCA2 fine-Tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev. Cell 22, 295-308 (2012).
142. Park, I. et al. Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation. J. Cell Biol. 202, 295-309 (2013).
143. Chan, K. L., Palmai-Pallag, T., Ying, S. & Hickson, I. D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nature Cell Biol. 11, 753-760 (2009).
144. Guervilly, J. H. et al. The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. Mol. Cell 57, 123-137 (2015).
145. Ouyang, J. et al. Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. Mol. Cell 57, 108-122 (2015).
146. Ouyang, K. J. et al. SUMO modification regulates BLM and RAD51 interaction at damaged replication forks. PLoS Biol. 7, e1000252 (2009).
147. Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53-58 (2012).
148. Daniels, M. J., Wang, Y., Lee, M. & Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876-879 (2004).
149. Jonsdottir, A. B. et al. Tetraploidy in BRCA2 breast tumours. Eur. J. Cancer 48, 305-310 (2012).
150. Jonsdottir, A. B. et al. BRCA2 heterozygosity delays cytokinesis in primary human fibroblasts. Cell Oncol. 31, 191-201 (2009).
151. Takaoka, M., Saito, H., Takenaka, K., Miki, Y. & Nakanishi, A. BRCA2 phosphorylated by PLK1 moves to the midbody to regulate cytokinesis mediated by nonmuscle myosin IIC. Cancer Res. 74, 1518-1528 (2014).
152. Mondal, G. et al. BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev. Cell 23, 137-152 (2012).
153. Pawlikowska, P., Fouchet, P., Vainchenker, W., Rosselli, F. & Naim, V. Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca-/- mice. Blood 124, 3613-3623 (2014).
154. Alavattam, K. G. et al. Elucidation of the Fanconi anemia protein network in meiosis and its function in the regulation of histone modifications. Cell Rep. 17, 1141-1157 (2016).
155. Kato, Y. et al. FANCB is essential in the male germline and regulates H3K9 methylation on the sex chromosomes during meiosis. Hum. Mol. Genet. 24, 5234-5249 (2015).
156. Cuomo, M. E. et al. p53-driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nature Cell Biol. 10, 723-730 (2008).
157. Mikule, K. et al. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nature Cell Biol. 9, 160-170 (2007).
158. Ceccaldi, R. et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 11, 36-49 (2012).
159. Ceccaldi, R. et al. Spontaneous abrogation of the G2DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J. Clin. Invest. 121, 184-194 (2011).
160. Freie, B. et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102, 4146-4152 (2003).
161. Woo, H. I. et al. Acute myeloid leukemia with complex hypodiploidy and loss of heterozygosity of 17p in a boy with Fanconi anemia. Ann. Clin. Lab Sci. 41, 66-70 (2011).
162. Quentin, S. et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117, e161-170 (2011).
163. Zanier, R., Briot, D., Dugas du Villard, J. A., Sarasin, A. & Rosselli, F. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Oncogene 23, 5004-5013 (2004).
164. Rathbun, R. K. et al. Interferon-γ-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 96, 4204-4211 (2000).
165. Haneline, L. S. et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 91, 4092-4098 (1998).
166. Rathbun, R. K. et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 90, 974-985 (1997).
167. Li, J. et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J. Clin. Invest. 117, 3283-3295 (2007).
168. Du, W., Erden, O. & Pang, Q. TNF-α signaling in Fanconi anemia. Blood Cells Mol. Dis. 52, 2-11 (2014).
169. Fagerlie, S. R. & Bagby, G. C. Immune defects in Fanconi anemia. Crit. Rev. Immunol. 26, 81-96 (2006).
170. Sies, H. Oxidative stress: A concept in redox biology and medicine. Redox Biol. 4, 180-183 (2015).
171. Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931-947 (2013).
172. Fritz, K. S. & Petersen, D. R. An overview of the chemistry and biology of reactive aldehydes. Free Radic. Biol. Med. 59, 85-91 (2013).
173. Kumari, U., Ya Jun, W., Huat Bay, B. & Lyakhovich, A. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. Oncogene 33, 165-172 (2014).
174. Baan, R. et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 8, 292-293 (2007).
175. Phillips, D. H. & Venitt, S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. Int. J. Cancer 131, 2733-2753 (2012).
176. Chang, J. S., Hsiao, J. R. & Chen, C. H. ALDH2 polymorphism and alcohol-related cancers in Asians: A public health perspective. J. Biomed. Sci. 24, 19 (2017).
177. Klyosov, A. A., Rashkovetsky, L. G., Tahir, M. K. & Keung, W. M. Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Biochemistry 35, 4445-4456 (1996).
178. Brooks, P. J., Enoch, M. A., Goldman, D., Li, T. K. & Yokoyama, A. The alcohol flushing response: An unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Med. 6, e50 (2009).
179. Harada, S., Agarwal, D. P. & Goedde, H. W. Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese. Lancet 2, 982 (1981).
180. Joenje, H., Arwert, F., Eriksson, A. W., de Koning, H. & Oostra, A. B. Oxygen-dependence of chromosomal aberrations in Fanconi?s anaemia. Nature 290, 142-143 (1981).
181. Pagano, G. et al. Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways. Eur. J. Haematol. 91, 141-151 (2013).
182. Du, W. et al. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 119, 4142-4151 (2012).
183. Mukhopadhyay, S. S. et al. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J. Cell Biol. 175, 225-235 (2006).
184. Saadatzadeh, M. R., Bijangi-Vishehsaraei, K., Hong, P., Bergmann, H. & Haneline, L. S. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway. J. Biol. Chem. 279, 16805-16812 (2004).
185. Uziel, O. et al. Oxidative stress causes telomere damage in Fanconi anaemia cells-A possible predisposition for malignant transformation. Br. J. Haematol. 142, 82-93 (2008).
186. Pagano, G. et al. In vitro hypersensitivity to oxygen of Fanconi anemia (FA) cells is linked to ex vivo evidence for oxidative stress in FA homozygotes and heterozygotes. Blood 89, 1111-1112 (1997).
187. Wilson, H. D., Wilson, J. R. & Fuchs, P. N. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res. 1098, 126-128 (2006).
188. Hadjur, S. et al. Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase. Blood 98, 1003-1011 (2001).
189. Langevin, F., Crossan, G. P., Rosado, I. V., Arends, M. J. & Patel, K. J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53-58 (2011).
190. Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571-575 (2012).
191. Oberbeck, N. et al. Maternal aldehyde elimination during pregnancy preserves the fetal genome. Mol. Cell 55, 807-817 (2014).
192. Pontel, L. B. et al. Endogenous formaldehyde is a hematopoietic stem cell genotoxin and metabolic carcinogen. Mol. Cell 60, 177-188 (2015).
193. Hira, A. et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122, 3206-3209 (2013)
194. Brooks, P. J. & Zakhari, S. Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis. Environ. Mol. Mutag. 55, 77-91 (2014).
195. Zhang, Q. S. et al. Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. Blood 116, 5140-5148 (2010).
196. Zhang, Q. S. et al. Evaluation of resveratrol and N-Acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model. Pediatr. Blood Cancer 61, 740-742 (2014).
197. Hamidieh, A. A. et al. Calcitriol for oral mucositis prevention in patients with fanconi anemia undergoing hematopoietic SCT: A double-blind, randomized, placebo-controlled trial. Am. J. Ther. 23, e1700-e1708 (2016).
198. Nam, J. S. et al. Application of bioactive quercetin in oncotherapy: from nutrition to nanomedicine. Molecules 21, E108 (2016).
199. Leyva-Lopez, N., Gutierrez-Grijalva, E. P., Ambriz-Perez, D. L. & Heredia, J. B. Flavonoids as cytokine modulators: A possible therapy for inflammation-related diseases. Int. J. Mol. Sci. 17, E921 (2016).
200. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01720147 (2017).
201. Taniguchi, T. et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568-574 (2003).
202. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
203. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
204. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
205. Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152-1158 (2017).
206. Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D?Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009).
207. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440-1449 (2007).
208. Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244-250 (2015).
209. Kim, G. et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline brca-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257-4261 (2015).
210. Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555-3561 (2010).
211. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852-861 (2014).
212. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382-1392 (2012).
213. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274-1284 (2017).
214. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01989546 (2017).
215. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02571725 (2017).
216. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02873975 (2017).
217. Patil, A. A. et al. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents. Oncotarget 5, 6414-6424 (2014).
218. Chirnomas, D. et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5, 952-961 (2006).
219. Landais, I. et al. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol. Cancer 8, 133 (2009).
220. Malric, A. et al. Fanconi anemia and solid malignancies in childhood: A national retrospective study. Pediatr. Blood Cancer 62, 463-470 (2015).
221. Dodgshun, A. J., Sexton-Oates, A., Saffery, R. & Sullivan, M. J. Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. Cancer Genet. 209, 53-56 (2016).
222. Hirsch, B. et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103, 2554-2559 (2004).
223. Wagner, J. E. et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103, 3226-3229 (2004).
224. Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39, 162-164 (2007).
225. Faivre, L. et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. Eur. Fanconi Anemia Res. Group. Blood 96, 4064-4070 (2000).
226. Futaki, M. et al. The IVS4 + 4 A to T mutation of the fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 95, 1493-1498 (2000).
227. Parmar, K., D?Andrea, A. & Niedernhofer, L. J. Mouse models of Fanconi anemia. Mutat. Res. 668, 133-140 (2009).
228. Pulliam-Leath, A. C. et al. Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. Blood 116, 2915-2920 (2010).
229. Walter, D. et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature 520, 549-552 (2015).
230. Cerabona, D., Sun, Z. & Nalepa, G. Leukemia and chromosomal instability in aged Fancc-/- mice. Exp. Hematol. 44, 352-357 (2016).
231. Qiao, F. et al. Phosphorylation of fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. J. Biol. Chem. 279, 46035-46045 (2004).
232. Wilson, J. B. et al. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. Mutat. Res. 689, 12-20 (2010).
233. Ho, G. P., Margossian, S., Taniguchi, T. & D?Andrea, A. D. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol. Cell. Biol. 26, 7005-7015 (2006).
234. Ishiai, M. et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat. Struct. Mol. Biol. 15, 1138-1146 (2008).
235. Andreassen, P. R., D?Andrea, A. D. & Taniguchi, T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18, 1958-1963 (2004).
236. Taniguchi, T. et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-472 (2002).
237. Zhi, G. et al. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res. 69, 8775-8783 (2009).
238. Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289-301 (2007).
239. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249-262 (2001).
240. Meetei, A. R. et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35, 165-170 (2003).
241. Cole, A. R., Lewis, L. P. & Walden, H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat. Struct. Mol. Biol. 17, 294-298 (2010).
242. Machida, Y. J. et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell 23, 589-596 (2006).
243. Hira, A. et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am. J. Hum. Genet. 96, 1001-1007 (2015).
244. Rickman, K. A. et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia. Cell Rep. 12, 35-41 (2015).
245. Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339 (2005).
246. Gibbs-Seymour, I. et al. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage. Mol. Cell 57, 150-164 (2015).
247. Kim, J. M. et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 16, 314-320 (2009).
248. Parmar, K. et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 28, 1186-1195 (2010).
249. Liang, Q. et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol. 10, 298-304 (2014).
250. Bogliolo, M. & Surralles, J. Fanconi anemia: A model disease for studies on human genetics and advanced therapeutics. Curr. Opin. Genet. Dev. 33, 32-40 (2015).
251. Bluteau, D. et al. Biallelic inactivation of REV7 is associated with Fanconi anemia. J. Clin. Invest. 126, 3580-3584 (2016).
252. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
253. Dror, Y. et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann. NY Acad. Sci. 1242, 40-55 (2011).
254. Stanley, S. E. & Armanios, M. The short and long telomere syndromes: paired paradigms for molecular medicine. Curr. Opin. Genet. Dev. 33, 1-9 (2015).